Ad­comm mem­ber who warned about risk of ap­prov­ing Bio­gen's ad­u­canum­ab has re­signed fol­low­ing his­toric OK — re­ports

One of the 11 ex­perts the FDA had con­vened to dis­cuss Bio­gen’s ad­u­canum­ab — be­fore over­rid­ing their rec­om­men­da­tion and ap­prov­ing the Alzheimer’s drug — has re­signed from …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER